Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;26(2):136-142.
doi: 10.1002/pds.4110. Epub 2016 Sep 26.

A Sudden and Unprecedented Increase in Low Dose Naltrexone (LDN) Prescribing in Norway. Patient and Prescriber Characteristics, and Dispense Patterns. A Drug Utilization Cohort Study

Affiliations
Free PMC article

A Sudden and Unprecedented Increase in Low Dose Naltrexone (LDN) Prescribing in Norway. Patient and Prescriber Characteristics, and Dispense Patterns. A Drug Utilization Cohort Study

Guttorm Raknes et al. Pharmacoepidemiol Drug Saf. .
Free PMC article

Abstract

Purpose: Following a TV documentary in 2013, there was a tremendous increase in low dose naltrexone (LDN) use in a wide range of unapproved indications in Norway. We aim to describe the extent of this sudden and unprecedented increase in LDN prescribing, to characterize patients and LDN prescribers, and to estimate LDN dose sizes.

Methods: LDN prescriptions recorded in the Norwegian Prescription Database (NorPD) in 2013 and 2014, and sales data not recorded in NorPD from the only Norwegian LDN manufacturer were included in the study.

Results: According to NorPD, 15 297 patients (0.3% of population) collected at least one LDN prescription. The actual number of users was higher as at least 23% of total sales were not recorded in NorPD. After an initial wave, there was a steady stream of new and persistent users throughout the study period. Median patient age was 52 years, and 74% of patients were female. Median daily dose was 3.7 mg. Twenty percent of all doctors and 71% of general medicine practitioners registered in Norway in 2014 prescribed LDN at least once.

Conclusions: The TV documentary on LDN in Norway was followed by a large increase in LDN prescribing, and the proportion of LDN users went from an insignificant number to 0.3% of the population. There was a high willingness to use and prescribe off label despite limited evidence. Observed median LDN dose, and age and gender distribution were as expected in typical LDN using patients. © 2016 The Authors. Pharmacoepidemiology and Drug Safety Published by John Wiley & Sons Ltd.

Keywords: drug utilization study; low dose naltrexone; off-label prescribing; pharmacoepidemiology; prescription database study.

Figures

Figure 1
Figure 1
Dispensed low dose naltrexone (LDN) prescriptions recorded in Norwegian Prescription Database (NorPD) by month. Total and repeated prescriptions. A documentary on LDN was aired 27 February 2013, and a LDN product was first included in NorPD from 15 May 2013 [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2
Figure 2
Median and mean naltrexone doses for all patients collecting more than LDN prescription [Color figure can be viewed at wileyonlinelibrary.com]

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles

References

    1. Tucker TK, Ritter AJ. Naltrexone in the treatment of heroin dependence: a literature review. Drug Alcohol Rev 2000; 19: 73–82.
    1. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345: 1734–9. - PubMed
    1. Raknes G, Giverhaug T. Naltrexone—high expectations to low dosages. Tidsskr Nor Laegeforen 2011; 131: 844–6. - PubMed
    1. Cree BAC, Kornyeyeva E, Goodin DS. Pilot trial of low‐dose naltrexone and quality of life in multiple sclerosis. Ann Neurol 2010; 68: 145–50. - PubMed
    1. Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo‐controlled trial. Dig Dis Sci 2011; 56: 2088–97. - PMC - PubMed

Publication types

MeSH terms

Feedback